Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients.

Massimiliano Mirabella, Giovanni Frisullo, Viviana Nociti, Raffaele Iorio, Agata Katia Patanella, Assunta Bianco, Cristina Sancricca, Marcella Caggiula, Pietro Attilio Tonali, Anna Paola Batocchi

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

23 Citazioni (Scopus)

Abstract

High dose glucocorticoid (GC) treatment has been demonstrated to have a short-term beneficial effect on functional recovery in relapsing multiple sclerosis (MS) patients but the exact mechanism of action of GCs in MS is unclear. We found that high dose intravenous GCs strongly reduced T-bet and pSTAT1 expression in CD4+, CD8+, CD14+ circulating cells in RRMS patients in relapse. pSTAT1and T-bet reduction was associated with the decline of IFNgamma production by PBMCs. A significant increase of AV-positive CD4+ and CD8+ T cells was detectable after GC treatment without any variation in the percentage of annexin V-positive monocytes. By in vitro analysis, patients during relapse, either before or after GC treatment, exhibited a lower proportion of apoptotic lymphocytes than remitting patients and controls. Our study suggests that GCs can modulate T-bet and STAT1 expression and that IFNgamma signalling inhibition contributes to anti-inflammatory action of GCs in the treatment of relapses of MS patients
Lingua originaleEnglish
pagine (da-a)284-293
Numero di pagine10
RivistaClinical Immunology
Stato di pubblicazionePubblicato - 2007

Keywords

  • corticosteroids
  • multiple sclerosis
  • transcription factor

Fingerprint Entra nei temi di ricerca di 'Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients.'. Insieme formano una fingerprint unica.

Cita questo